LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants
and services, today reported Q2 2023 results, announced a
$0.14/share quarterly dividend and provided guidance.
Q2 2023 Financial Results
- Sales $50.1mm, +19% (+16% organic)
vs. Q2 2022
- Op. income $9.5mm, +63% (+8%
adjusted)
- Op. margin 19%
- Net income $8.1mm, +130% (+27%
adjusted)
- Earnings per diluted share $0.36,
+127% (+25% adjusted)
- Cash up $9.2mm to $90.2mm
Bovine patches (+16%), valvulotomes (+18%), bovine grafts
(+13%), carotid shunts (+22%) and allografts (+18%) drove Q2 sales.
EMEA was up 26%, APAC 21% and the Americas 16%.
The gross margin decreased to 64.0% in Q2 (vs. 66.0% in Q2
2022), driven by manufacturing inefficiencies and distribution
sales of porcine patches, partially offset by price increases.
Operating income of $9.5mm was up 63% vs. Q2 2022. Excluding St.
Etienne factory closure charges, operating income was up 8%.
Operating expenses (excluding St. Etienne charges) grew 19% due to
sales rep growth and higher commissions, as well as CE-related
regulatory costs.
George LeMaitre, Chairman and CEO, said “16% organic sales
growth and 25% adjusted EPS growth was a result of increased
hospital procedures and our 9% price increase. In retrospect, our
2022 hiring surge seems well-timed.”
Business Outlook
|
Q3 2023 Guidance |
Q4 2023 Guidance |
Full Year 2023 Guidance |
Sales |
$46.5mm - $48.9mm(Mid: $47.7mm, +22%,+16% Org.) |
$49.3mm - $51.7mm(Mid: $50.5mm, +23%,+17% Org.) |
$193.0mm - $197.8mm(Mid: $195.4mm, +21%,+18% Org.) |
Gross Margin |
64.3% |
64.6% |
64.6% |
|
Op. Inc. |
$7.4mm - $8.9mm(Mid: $8.2mm, +33%) |
$8.7mm - $10.2mm(Mid: $9.4mm, +36%) |
$33.4mm - $36.5mm(Mid $34.9mm, +30%) |
Op. Inc. Ex-Special* |
- |
- |
$33.9mm - $37.0mm(Mid $35.4mm, +18%) |
EPS |
$0.28 - $0.33(Mid: $0.31, +24%) |
$0.32 - $0.38(Mid: $0.35, +39%) |
$1.23 - $1.34(Mid: $1.28, +38%) |
EPS Ex-Special* |
- |
- |
$1.25 - $1.35(Mid: $1.30, +22%) |
*Special charges are related to the St. Etienne factory
closure.
Quarterly Dividend
On July 25, 2023, the Company's Board of Directors approved
a quarterly dividend of $0.14/share of common stock. The
dividend will be paid on August 31, 2023 to shareholders
of record on August 17, 2023.
Share Repurchase Program
On February 21, 2023, the Company's Board of Directors
authorized the repurchase of up to $25.0mm of the Company’s common
stock. The repurchase program may be suspended or discontinued at
any time and will conclude on February 21, 2024, unless extended by
the Board.
Conference Call Reminder
Management will conduct a conference call at 5:00pm
ET today. The conference call will be broadcast live over the
Internet. Individuals interested in listening to the webcast can
log on to the Company's website at www.lemaitre.com/investor.
Access to the live call is available by registering online here.
All registrants will receive dial-in information and a PIN allowing
them to access the live call. The audio webcast can also be
accessed live or via replay through a webcast at
www.lemaitre.com/investor. For individuals unable to join the live
conference call, a replay will be available on the Company's
website.
A reconciliation of GAAP to non-GAAP results is included in the
tables attached to this release.
About LeMaitre
LeMaitre is a provider of devices, implants and services
for the treatment of peripheral vascular disease, a condition that
affects more than 200 million people worldwide. The Company
develops, manufactures and markets disposable and implantable
vascular devices to address the needs of its core customer, the
vascular surgeon.
LeMaitre is a registered trademark of LeMaitre Vascular,
Inc. This press release may include other trademarks and trade
names of the Company.
For more information about the Company, please
visit www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre management believes that in order to better
understand the Company's short- and long-term financial trends,
investors may wish to consider certain non-GAAP financial measures
as a supplement to financial performance measures prepared in
accordance with GAAP. Non-GAAP financial measures are not based on
a comprehensive set of accounting rules or principles and do not
have standardized meanings. These non-GAAP measures result from
facts and circumstances that may vary in frequency and/or impact on
continuing operations. Non-GAAP measures should be considered in
addition to, and not as a substitute for, financial performance
measures in accordance with GAAP. In addition to the description
provided below, reconciliation of GAAP to non-GAAP results is
provided in the financial statement tables included in this press
release.
In this press release, the Company has reported non-GAAP sales
growth percentages after adjusting for the impact of foreign
currency exchange, business development transactions, and/or other
events, including EBITDA. This press release also provides guidance
for operating income and EPS excluding the special charge relating
to the closure of our St. Etienne factory and revenue related the
Aziyo distribution agreement. The Company refers to the calculation
of non-GAAP sales growth percentages as "organic." The Company
analyzes non-GAAP sales on a constant currency basis, net of
acquisitions and other non-recurring events, and the aforementioned
non-GAAP profitability measures to better measure the comparability
of results between periods. Because changes in foreign currency
exchange rates have a non-operating impact on net sales, and
acquisitions, divestitures, product discontinuations, factory
closures, and other strategic transactions are episodic in nature
and are highly variable to the reported sales results, the Company
believes that evaluating growth in sales on a constant currency
basis net of such transactions provides an additional and
meaningful assessment of sales to management. The Company believes
that the presentation of guidance described above for operating
income and EPS provides an alternative and meaningful view of the
Company’s profitability.
Forward-Looking Statements
The Company's current financial results, as discussed in this
release, are preliminary and unaudited, and subject to adjustment.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995. Statements in this press release regarding the Company's
business that are not historical facts may be "forward-looking
statements" that involve risks and uncertainties. Forward-looking
statements are based on management's current, preliminary
expectations and are subject to risks and uncertainties that could
cause actual results to differ from the results expected,
including, but not limited to, the status of our global regulatory
approvals and compliance with regulatory requirements to market and
sell our products both in the U.S. and outside of the U.S.; the
risk of significant fluctuations in our quarterly and annual
results due to numerous factors; the risk that assumptions about
the market for the Company’s products and the productivity of the
Company’s direct sales force and distributors may not be correct;
the risk that we may not be able to maintain our recent levels of
profitability; the risk that the Company may not realize the
anticipated benefits of its strategic activities; risks related to
the integration of acquisition targets; the acceleration or
deceleration of product growth rates; risks related to product
demand and market acceptance of the Company’s products and pricing;
the risk that a recall of our products could result in significant
costs or negative publicity; the risk that the Company is not
successful in transitioning to a direct-selling model in new
territories and other risks and uncertainties included under the
heading "Risk Factors" in our most recent Annual Report on Form
10-K, as updated by our subsequent filings with the SEC, which
are all available on the Company's investor relations website
at http://www.lemaitre.com and on
the SEC's website at http://www.sec.gov. Undue
reliance should not be placed on forward-looking statements, which
speak only as of the date they are made. The Company undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events, or circumstances after the date
they were made, or to reflect the occurrence of unanticipated
events.
CONTACT: J.J. Pellegrino, CFO,
LeMaitre781-425-1691jjpellegrino@lemaitre.com
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) |
|
|
|
|
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30, 2023 |
|
December 31, 2022 |
|
|
|
|
(unaudited) |
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
Cash and cash
equivalents |
|
$ |
19,488 |
|
|
$ |
19,134 |
|
|
|
Short-term marketable securities |
|
|
70,689 |
|
|
|
63,557 |
|
|
|
Accounts receivable, net |
|
|
26,406 |
|
|
|
22,040 |
|
|
|
Inventory and other deferred costs |
|
|
53,831 |
|
|
|
50,271 |
|
|
|
Prepaid expenses and other current assets |
|
|
4,076 |
|
|
|
6,731 |
|
|
Total current assets |
|
|
174,490 |
|
|
|
161,733 |
|
|
|
|
|
|
|
|
|
Property and equipment, net |
|
|
21,217 |
|
|
|
17,901 |
|
|
Right-of-use leased assets |
|
|
15,804 |
|
|
|
15,634 |
|
|
Goodwill |
|
|
65,945 |
|
|
|
65,945 |
|
|
Other intangibles, net |
|
|
43,999 |
|
|
|
46,527 |
|
|
Deferred tax assets |
|
|
2,081 |
|
|
|
1,745 |
|
|
Other assets |
|
|
2,931 |
|
|
|
991 |
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
326,467 |
|
|
$ |
310,476 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders' equity |
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
Accounts
payable |
|
$ |
3,519 |
|
|
$ |
2,903 |
|
|
|
Accrued
expenses |
|
|
19,327 |
|
|
|
19,967 |
|
|
|
Acquisition-related obligations |
|
|
651 |
|
|
|
573 |
|
|
|
Lease
liabilities - short-term |
|
|
2,358 |
|
|
|
1,886 |
|
|
Total current liabilities |
|
|
25,855 |
|
|
|
25,329 |
|
|
|
|
|
|
|
|
|
Lease liabilities - long-term |
|
|
14,449 |
|
|
|
14,710 |
|
|
Deferred tax liabilities |
|
|
72 |
|
|
|
69 |
|
|
Other long-term liabilities |
|
|
2,264 |
|
|
|
2,167 |
|
|
Total liabilities |
|
|
42,640 |
|
|
|
42,275 |
|
|
|
|
|
|
|
|
|
Stockholders' equity |
|
|
|
|
|
|
Common
stock |
|
|
239 |
|
|
|
237 |
|
|
|
Additional
paid-in capital |
|
|
196,941 |
|
|
|
189,268 |
|
|
|
Retained
earnings |
|
|
105,696 |
|
|
|
97,773 |
|
|
|
Accumulated
other comprehensive loss |
|
|
(5,822 |
) |
|
|
(6,031 |
) |
|
|
Treasury
stock |
|
|
(13,227 |
) |
|
|
(13,046 |
) |
|
Total stockholders' equity |
|
|
283,827 |
|
|
|
268,201 |
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders' equity |
|
$ |
326,467 |
|
|
$ |
310,476 |
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) |
|
|
|
|
|
|
CONDENSED CONSOLIDATED STATEMENT OF
OPERATIONS |
|
|
|
|
(amounts in thousands, except per share amounts) |
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
For the six months ended |
|
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
|
|
|
|
|
|
|
|
Net sales |
$ |
50,115 |
|
$ |
42,108 |
|
|
$ |
97,190 |
|
|
$ |
81,669 |
|
Cost of sales |
|
18,029 |
|
|
14,298 |
|
|
|
34,221 |
|
|
|
27,897 |
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
32,086 |
|
|
27,810 |
|
|
|
62,969 |
|
|
|
53,772 |
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
Sales and marketing |
|
10,216 |
|
|
8,242 |
|
|
|
21,113 |
|
|
|
16,092 |
|
General and administrative |
|
7,722 |
|
|
7,331 |
|
|
|
15,654 |
|
|
|
14,583 |
|
Research and development |
|
4,516 |
|
|
3,346 |
|
|
|
8,391 |
|
|
|
6,278 |
|
Restructuring |
|
180 |
|
|
3,107 |
|
|
|
485 |
|
|
|
3,107 |
|
Total operating expenses |
|
22,634 |
|
|
22,026 |
|
|
|
45,643 |
|
|
|
40,060 |
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
9,452 |
|
|
5,784 |
|
|
|
17,326 |
|
|
|
13,712 |
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
Interest income |
|
682 |
|
|
167 |
|
|
|
1,250 |
|
|
|
275 |
|
Foreign currency gain (loss) |
|
185 |
|
|
(403 |
) |
|
|
(240 |
) |
|
|
(443 |
) |
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
10,319 |
|
|
5,548 |
|
|
|
18,336 |
|
|
|
13,544 |
|
|
|
|
|
|
|
|
|
|
Provision for income taxes |
|
2,221 |
|
|
2,033 |
|
|
|
4,198 |
|
|
|
3,991 |
|
|
|
|
|
|
|
|
|
|
Net income |
$ |
8,098 |
|
$ |
3,515 |
|
|
$ |
14,138 |
|
|
$ |
9,553 |
|
|
|
|
|
|
|
|
|
|
Earnings per share of common stock |
|
|
|
|
|
|
|
Basic |
$ |
0.36 |
|
$ |
0.16 |
|
|
$ |
0.64 |
|
|
$ |
0.44 |
|
Diluted |
$ |
0.36 |
|
$ |
0.16 |
|
|
$ |
0.63 |
|
|
$ |
0.43 |
|
|
|
|
|
|
|
|
|
|
Weighted - average shares outstanding: |
|
|
|
|
|
|
|
Basic |
|
22,213 |
|
|
21,958 |
|
|
|
22,162 |
|
|
|
21,947 |
|
Diluted |
|
22,451 |
|
|
22,129 |
|
|
|
22,371 |
|
|
|
22,115 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends declared per common share |
|
$ |
0.140 |
|
$ |
0.125 |
|
|
$ |
0.280 |
|
|
$ |
0.250 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) |
|
|
|
|
|
|
|
|
|
|
|
|
SELECTED NET SALES INFORMATION |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
For the six months ended |
|
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
|
$ |
|
% |
|
$ |
|
% |
|
$ |
|
% |
|
$ |
|
% |
Net Sales by Geography |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Americas |
$ |
33,507 |
|
67% |
|
$ |
28,854 |
|
69% |
|
$ |
65,633 |
|
67% |
|
$ |
55,397 |
|
68% |
|
Europe,
Middle East and Africa |
|
13,580 |
|
27% |
|
|
10,749 |
|
25% |
|
|
25,857 |
|
27% |
|
|
21,243 |
|
26% |
|
Asia
Pacific |
|
3,028 |
|
6% |
|
|
2,505 |
|
6% |
|
|
5,700 |
|
6% |
|
|
5,029 |
|
6% |
Total Net Sales |
$ |
50,115 |
|
100% |
|
$ |
42,108 |
|
100% |
|
$ |
97,190 |
|
100% |
|
$ |
81,669 |
|
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT) |
|
|
|
|
|
|
|
|
|
NON-GAAP FINANCIAL MEASURES |
|
|
|
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended |
|
For the six months ended |
|
|
|
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
Reconciliation between GAAP and Non-GAAP EBITDA |
|
|
|
|
|
|
|
|
|
|
Net income as reported |
|
$ |
8,098 |
|
|
$ |
3,515 |
|
|
$ |
14,138 |
|
|
$ |
9,553 |
|
|
|
Interest (income) expense, net |
|
|
(682 |
) |
|
|
(167 |
) |
|
|
(1,250 |
) |
|
|
(275 |
) |
|
|
Amortization and depreciation expense |
|
|
2,326 |
|
|
|
2,444 |
|
|
|
4,677 |
|
|
|
4,817 |
|
|
|
Provision for income taxes |
|
|
2,221 |
|
|
|
2,033 |
|
|
|
4,198 |
|
|
|
3,991 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA |
|
$ |
11,963 |
|
|
$ |
7,825 |
|
|
$ |
21,763 |
|
|
$ |
18,086 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBITDA percentage increase |
|
|
|
|
53 |
% |
|
|
|
|
20 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LEMAITRE VASCULAR, INC. (NASDAQ: LMAT) |
|
|
|
|
|
|
|
NON-GAAP FINANCIAL MEASURES |
|
|
|
|
|
|
|
(amounts in thousands) |
|
|
|
|
|
|
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP sales growth: |
|
|
|
|
|
|
|
|
For the three months ended June 30, 2023 |
|
|
|
|
|
|
|
|
|
Net sales as reported |
|
$ |
50,115 |
|
|
|
|
|
|
|
|
Net
distribution sales |
|
|
(1,233 |
) |
|
|
|
|
|
|
|
Impact of
currency exchange rate fluctuations |
|
|
12 |
|
|
|
|
|
|
|
|
Adjusted net sales |
|
|
|
$ |
48,894 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, 2022 |
|
|
|
|
|
|
|
|
|
Net sales as
reported |
|
$ |
42,108 |
|
|
|
|
|
|
|
|
Adjusted net sales |
|
|
|
$ |
42,108 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted net
sales increase for the three months ended June 30, 2023 |
|
|
|
$ |
6,786 |
|
16% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP operating income
growth: |
|
|
|
|
|
|
|
|
For the three months ended June 30, 2023 |
|
|
|
|
|
|
|
|
|
Operating
income as reported |
|
$ |
9,452 |
|
|
|
|
|
|
|
|
Impact of
special charge |
|
|
180 |
|
|
|
|
|
|
|
|
Adjusted operating income |
|
|
|
$ |
9,632 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, 2022 |
|
|
|
|
|
|
|
|
|
Operating
income as reported |
|
$ |
5,784 |
|
|
|
|
|
|
|
|
Impact of
special charge |
|
|
3,107 |
|
|
|
|
|
|
|
|
Adjusted operating income |
|
|
|
$ |
8,891 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating income increase for the three months ended June 30,
2023 |
|
|
|
$ |
741 |
|
8% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP net income growth: |
|
|
|
|
|
|
|
|
For the three months ended June 30, 2023 |
|
|
|
|
|
|
|
|
|
Net income
as reported |
|
$ |
8,098 |
|
|
|
|
|
|
|
|
Impact of
special charge, including tax |
|
|
134 |
|
|
|
|
|
|
|
|
Adjusted net income |
|
|
|
$ |
8,232 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, 2022 |
|
|
|
|
|
|
|
|
|
Net income
as reported |
|
$ |
3,515 |
|
|
|
|
|
|
|
|
Impact of
special charge, including tax |
|
|
2,986 |
|
|
|
|
|
|
|
|
Adjusted net income |
|
|
|
$ |
6,501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted net
income increase for the three months ended June 30, 2023 |
|
|
|
$ |
1,731 |
|
27% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP EPS growth: |
|
|
|
|
|
|
|
|
For the three months ended June 30, 2023 |
|
|
|
|
|
|
|
|
|
EPS as
reported |
|
$ |
0.36 |
|
|
|
|
|
|
|
|
Impact of
special charge, including tax |
|
|
0.01 |
|
|
|
|
|
|
|
|
Adjusted EPS |
|
|
|
$ |
0.37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, 2022 |
|
|
|
|
|
|
|
|
|
EPS as
reported |
|
$ |
0.16 |
|
|
|
|
|
|
|
|
Impact of
special charge, including tax |
|
|
0.13 |
|
|
|
|
|
|
|
|
Adjusted EPS |
|
|
|
$ |
0.29 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted EPS
increase for the three months ended June 30, 2023 |
|
|
|
$ |
0.08 |
|
25% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP operating expense
growth: |
|
|
|
|
|
|
|
|
For the three months ended June 30, 2023 |
|
|
|
|
|
|
|
|
|
Operating
expenses as reported |
|
$ |
22,634 |
|
|
|
|
|
|
|
|
Impact of
special charge |
|
|
(180 |
) |
|
|
|
|
|
|
|
Adjusted operating expenses |
|
|
|
$ |
22,454 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, 2022 |
|
|
|
|
|
|
|
|
|
Operating
expenses as reported |
|
$ |
22,026 |
|
|
|
|
|
|
|
|
Impact of
special charge |
|
|
(3,107 |
) |
|
|
|
|
|
|
|
Adjusted operating expenses |
|
|
|
$ |
18,919 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating expense increase for the three months ended June 30,
2023 |
|
|
|
$ |
3,535 |
|
19% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP projected sales
growth: |
|
|
|
|
|
|
|
|
For the three months ending September 30, 2023 |
|
|
|
|
|
|
|
|
|
Net sales
per guidance (midpoint) |
|
$ |
47,707 |
|
|
|
|
|
|
|
|
Net
distribution sales |
|
|
(1,667 |
) |
|
|
|
|
|
|
|
Impact of
currency exchange rate fluctuations |
|
|
(866 |
) |
|
|
|
|
|
|
|
Adjusted projected net sales |
|
|
|
$ |
45,174 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended September 30, 2022 |
|
|
|
|
|
|
|
|
|
Net sales as
reported |
|
$ |
39,028 |
|
|
|
|
|
|
|
|
Adjusted net sales |
|
|
|
$ |
39,028 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
projected net sales increase for the three months ending September
30, 2023 |
|
|
|
$ |
6,146 |
|
16% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP projected sales
growth: |
|
|
|
|
|
|
|
|
For the three months ending December 31, 2023 |
|
|
|
|
|
|
|
|
|
Net sales
per guidance (midpoint) |
|
$ |
50,500 |
|
|
|
|
|
|
|
|
Net
distribution sales |
|
|
(1,600 |
) |
|
|
|
|
|
|
|
Impact of
currency exchange rate fluctuations |
|
|
(1,020 |
) |
|
|
|
|
|
|
|
Adjusted projected net sales |
|
|
|
$ |
47,880 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended December 31, 2022 |
|
|
|
|
|
|
|
|
|
Net sales as
reported |
|
$ |
40,954 |
|
|
|
|
|
|
|
|
Adjusted net sales |
|
|
|
$ |
40,954 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
projected net sales increase for the three months ending December
31, 2023 |
|
|
|
$ |
6,926 |
|
17% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP projected sales
growth: |
|
|
|
|
|
|
|
|
For the year ending December 31, 2023 |
|
|
|
|
|
|
|
|
|
Net sales
per guidance (midpoint) |
|
$ |
195,397 |
|
|
|
|
|
|
|
|
Net
distribution sales |
|
|
(4,500 |
) |
|
|
|
|
|
|
|
Impact of
currency exchange rate fluctuations |
|
|
(824 |
) |
|
|
|
|
|
|
|
Adjusted projected net sales |
|
|
|
$ |
190,073 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2022 |
|
|
|
|
|
|
|
|
|
Net sales as
reported |
|
$ |
161,651 |
|
|
|
|
|
|
|
|
Adjusted net sales |
|
|
|
$ |
161,651 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
projected net sales increase for the year ending December 31,
2023 |
|
|
|
$ |
28,422 |
|
18% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP projected operating
income: |
|
|
|
|
|
|
|
|
For the year ending December 31, 2023 |
|
|
|
|
|
|
|
|
|
Operating
income per guidance (midpoint) |
|
$ |
34,917 |
|
|
|
|
|
|
|
|
Impact of
special charge |
|
|
485 |
|
|
|
|
|
|
|
|
Adjusted projected operating income |
|
|
|
$ |
35,402 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2022 |
|
|
|
|
|
|
|
|
|
Operating
income as reported |
|
$ |
26,829 |
|
|
|
|
|
|
|
|
Impact of
special charge |
|
|
3,107 |
|
|
|
|
|
|
|
|
Adjusted operating income |
|
|
|
$ |
29,936 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
projected operating income increase for the year ending December
31, 2023 |
|
|
|
$ |
5,466 |
|
18% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP projected EPS: |
|
|
|
|
|
|
|
|
For the year ending December 31, 2023 |
|
|
|
|
|
|
|
|
|
EPS per
guidance (midpoint) |
|
$ |
1.28 |
|
|
|
|
|
|
|
|
Impact of
special charge, including tax |
|
|
0.02 |
|
|
|
|
|
|
|
|
Adjusted EPS |
|
|
|
$ |
1.30 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended December 31, 2022 |
|
|
|
|
|
|
|
|
|
EPS as
reported |
|
$ |
0.93 |
|
|
|
|
|
|
|
|
Impact of
special charge, including tax |
|
|
0.13 |
|
|
|
|
|
|
|
|
Adjusted EPS |
|
|
|
$ |
1.06 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
projected EPS increase for the year ending December 31, 2023 |
|
|
|
$ |
0.24 |
|
22% |
|
|
|
|
|
|
|
|
|
|
|
LeMaitre Vascular (NASDAQ:LMAT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
LeMaitre Vascular (NASDAQ:LMAT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024